BRIM Biotechnology has initiated the Phase 3 clinical trial of BRM421 for the treatment of Dry Eye Disease and enrolled the first patient in the trial. This multicenter, double-blind, randomized, vehicle-controlled trial will enroll over 700 patients.

Glaukos announced positive results for a prospective, multicenter clinical trial designed to assess the safety of the surgical exchange procedure for iDose TR (travoprost intraocular implant) in subjects who had previously received an iDose TR.